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Most proteins at the plasma membrane are not uniformly distributed but localize to dynamic domains of 
nanoscale dimensions. To investigate their functional relevance, there is a need for methods that enable 
comprehensive analysis of the compositions and spatial organizations of membrane protein nanodomains in 
cell populations. Here we describe the development of a non-microscopy based method for ensemble 
analysis of membrane protein nanodomains. The method, termed NANOscale DEciphEring of membrane 
Protein nanodomains (NanoDeep), is based on the use of DNA nanoassemblies to translate membrane 
protein organization information into a DNA sequencing readout. Using NanoDeep, we characterised the 
nanoenvironments of Her2, a membrane receptor of critical relevance in cancer. Importantly, we were able to 
modulate by design the inventory of proteins analysed by NanoDeep. NanoDeep has the potential to provide 
new insights into the roles of the composition and spatial organization of protein nanoenvironments in the 
regulation of membrane protein function. 
 
Cells sense extracellular signals, such as protein ligands, through specialised proteins present on the cell 
surface called membrane receptors. The protein nanoenvironment, i.e. the composition and spatial 
organization of proteins surrounding membrane receptors, is dynamic and often modulated by ligand 
binding, suggesting that it has functional relevance1-5. Super-resolution microscopy has enabled the 
characterisation of the nanoscale spatial distributions of proteins at the cell membrane6, 7. Super-resolution 
imaging methods use detection of light emitted by fluorophores as a readout, which poses limitations on the 
number of proteins that can be analysed simultaneously. However, several recent developments such as 
PAINT8, 9 and maS3TORM10 enable increased multiplexing in super-resolution imaging by stochastic binding 
of fluorescently labelled DNA oligos or by serial imaging, respectively. Automation strategies have improved 
considerably sampling fractions in super-resolution imaging10, 11, but it is typically only feasible to image a 
small fraction of all protein nanodomains present in a cell population. DNA detection as a proxy for protein 
detection through the use of oligo-conjugated affinity binders has been used extensively for signal 
amplification12 and analysis of proximity between pairs of proteins13, 14. Further, DNA sequencing is used as a 
readout in DNA microscopy, a new method to visualize the spatial organization of RNA and DNA 
molecules inside cells15-17. Here we present NanoDeep, a method that uses DNA sequencing to decipher the 
nanoscale spatial distribution of membrane proteins. This method allows for the detection en masse of the 
inventory of proteins that forms the nanoenvironment of any reference membrane protein in cell 
populations. 
We demonstrate the application of NanoDeep to the analysis of protein nanoenvironments surrounding 
Human Epidermal Growth Factor Receptor 2 (Her2). Her2 cooperates with members of the Epithelial 
Growth Factor Receptor (EGFR) family of proteins (EGFR, Her2, Her3 and Her4) to regulate cell 
proliferation and differentiation during normal embryonic development18. Her2 is overexpressed in several 
cancers and its expression levels correlate with poor prognosis18, 19. Interestingly, the oncogenic capacity of 
Her2 is closely connected to the impact of overexpression on the frequency distributions of interactions 
between Her2 and EGFR family members at the cell membrane20-22. For example, Her2 overexpression leads 
to increased levels of Her2 and Her3 heterodimers, which drive more potent oncogenic signalling activity 
than the corresponding homodimers19, 23-25. Further, Her2-EGFR dimerization, driven by overexpression of 
one or both proteins, has been shown to lead to a more aggressive breast cancer phenotype26. Notably, new 
evidence supports the hypothesis that not only the formation of dimers but also of higher-order receptor 
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assemblies at cell membrane regulates Her2 function27-31. Although there are well established correlations 
between the levels of Her2 homo- and heterodimers and cancer aggressiveness, the roles of the composition 
of Her2 protein nanoenvironments for downstream signalling are poorly understood25. Using NanoDeep, we 
characterised the protein nanoenvironments of Her2 in model surfaces and in cells. We found that SKBR3 
breast cancer cells that overexpress Her2 showed similar levels of occupancy of Her2, Her3 and EGFR in 
Her2 nanoenvironments compared to MCF7 breast cancer cells, which present basal levels of Her2. 
However, the higher expression levels of Her2 in SKBR3 cells correlated with higher total levels of Her2, 
Her3 and EGFR in Her2 nanoenvironments, compared to MCF7 cells. Further, stimulation of SKBR3 cells 
with the Her3 ligand Heregulin-β1 (HRG-β1) led to an increase in occupancy of Her2 and Her3, and to a 
lesser extent of EGFR, in Her2 nanoevinronments. Together, these results indicate that NanoDeep is able to 
characterize differences in protein nanoenvironments in different cellular contexts.  
 
NanoDeep The NanoDeep method converts protein spatial distribution information into a DNA 
sequencing readout (Fig. 1). We designed a DNA nanoassembly, which we named NanoComb, composed of 
four single-stranded DNA (ssDNA) oligos, called prongs, that protrude from a double-stranded backbone at 
regular intervals. The prongs contain a barcode that identifies their position within the NanoComb. The first 
prong is defined as the reference prong and the remaining prongs are the detection prongs. The reference 
prong is preloaded with a binder that recognizes a reference protein, which is Her2 in our model workflow. 
This is done by conjugating the binder for the reference protein with an oligo that partially hybridizes with 
the reference prong (Fig. 1a). After incubating the NanoComb bearing the binder for the reference protein 
with fixed cells, a library of binders for the inventory of proteins to be analysed is added, each conjugated to 
an oligo containing a barcode that identifies the protein recognised by the binder (Fig. 1b). The oligos further 
contain a sequence, which is common to all binder-oligo conjugates, that is partially complementary to the 
detection prongs. Importantly, to prevent binder-oligo conjugates that are not bound to membrane proteins 
from hybridizing with the detection prongs, hybridization is blocked when conjugates are added to the cells 
and unblocked after washing away conjugates that are not bound to their target membrane proteins (Fig. 1c). 
The hybridization between the prongs and the binder oligos creates free 3’ ends that act as primers for DNA 
polymerase (Fig. 1d), leading to the formation of double-stranded DNA (dsDNA) sequences that contain 
both the barcode for the position of the prong as well as the binder barcode (Fig. 1e). As specific nuclease 
sequences are incorporated in both the prongs and binder oligos, these dsDNA sequences can be cleaved by 
a nuclease (Fig. 1f) and analysed by next generation sequencing (NGS) (Fig. 1g), providing information on 
the composition and spatial organization of the nanoenvironment surrounding the reference protein across 
the cell population. 
Super-resolution microscopy studies determined that the spacing of proteins in Her2 dimers is on average in 
the range of 10-20 nm21, 29, 32 and that Her2 clusters in breast carcinoma cell lines have a mean diameter of 67 
nm27. The detection prongs of the NanoCombs are positioned by design at 7, 14 and 21 nm relative to the 
reference prong, in an extended DNA conformation. As the NanoComb dimensions are below the 
persistence length of dsDNA, which is estimated to be around 50 nm33, it has limited molecular flexibility and 
can be considered as having linear conformation on average. Therefore, the geometry of NanoCombs enables 
probing of the relevant length scale for the analysis of Her2 nanoenvironments.  
 
Characterisation of NanoCombs and binder-oligo conjugates NanoCombs were produced by 
hybridizing a 100-nucleotide (nt) long ssDNA oligo (backbone) to four shorter oligos (prongs) partially 
complementary to the backbone (Fig. 2a,b). The prongs form a pattern of four ssDNA oligos with a period 
of 21 base pairs (bp), protruding from the same side of the backbone. The period of the prongs corresponds 
to a distance of 7 nm in an extended DNA conformation. The length of the protruding portion of the prongs 
is 36 and 31 bp for reference prong and detection prongs, respectively, corresponding to a maximum length 
of 12.5 nm, when double-stranded (Fig. 2a,b).  
After folding the NanoCombs, we removed the excess prongs by using streptavidin-coated magnetic beads 
and taking advantage of the lower affinity of desthiobiotin compared to biotin (Supplementary Fig. 1). We 
monitored the assembly of NanoCombs with Surface Plasmon Resonance (SPR) assay, showing sequential 
hybridization of the four prongs with the backbone (Fig. 2c). We further confirmed NanoComb assembly 
and purification with native polyacrylamide gel electrophoresis (PAGE), which showed that the four prongs 
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hybridised with the backbone (Fig. 2d) and that the NanoCombs were purified from excess prongs 
(Supplementary Fig. 1). 
We selected affibodies as binders due to their high affinity and small dimensions, minimizing the impact of 
the size of the binder per se on the spatial resolution of the method. To enable site specific conjugation with a 
stoichiometry of 1:1, we used a conjugation approach based on a self-labelling tag derived from a truncated 
VirD2 protein of Agrobacterium tumefaciens34. We produced fusion proteins between VirD2 and affibodies that 
bind the extracellular domains of three members of the EGFR family (EGFR, Her2 and Her3). SPR assay 
showed that all affibodies fused to VirD2 exhibited high affinity and selectivity for their specific targets 
(Extended Data Fig. 1). Further, native PAGE demonstrated efficient conjugation of the affibodies with the 
oligos (Extended Data Fig. 2a). We observed that the oligo conjugation caused a slight increase in the KD of 
the affibodies that nevertheless did not prevent them from recognizing their targets with high affinity since 
the KD was still in the nanomolar range, and, more significantly, the low dissociation rate (koff) was preserved 
(Extended Data Fig. 2b).  
To assess the hybridization of the affibody-oligo conjugates to the NanoCombs, we used direct (Fig. 2e) and 
reverse (Fig. 2f) SPR assays using anti-Her2 affibody-oligo conjugates as a test sample, which supported the 
specificity of the interaction between the NanoCombs and the affibody-oligo conjugates.  
 
Toehold exchange strategy for specific binder detection In the model workflow presented here, the 
targeting step in NanoDeep consists of binding NanoCombs preloaded with anti-Her2 affibody (Her2-
NanoCombs) to Her2. The detection step involves binding of anti-Her2, -Her3 and -EGFR affibody-oligo 
conjugates (binder library) to their targets and hybridization of the oligos to the detection prongs of the 
NanoCombs. Therefore, it is crucial that the hybridization of the binder library to the detection prongs of the 
NanoCombs occurs only when the affibodies are first bound to their target proteins. To address this, we 
developed a strategy based on toehold-mediated strand displacement35, 36, widely used in dynamic DNA 
nanotechnology. To validate this strategy, biotinylated versions of the binder oligos were anchored to 
streptavidin coated SPR surfaces (Extended Data Fig.3). Hybridization to a blocking strand caused an 
increase in the SPR signal, which was followed by a decrease in the signal due to displacement of the blocking 
strand through strand migration upon adding an invading strand. The resulting unblocked oligos were able to 
hybridize to the NanoCombs, which led to an increase in the SPR signal (Extended Data Fig.3a). In the 
absence of strand invasion, the blocked oligos were not able to bind to the NanoCombs (Extended Data 
Fig.3b). To verify that the affibody-oligo conjugates were able to hybridize, following toehold exchange, to 
the detection prongs of Her2-NanoCombs, we performed SPR assays using surfaces that presented both 
ECD-Her2 and ECD-Her3. Her2-NanoCombs were incubated with the functionalised SPR surfaces (Fig. 3). 
Following washing, anti-Her3 affibody-oligo conjugates that were pre-hybridised to blocking strands were 
injected. After allowing for binding of the conjugates to ECD-Her3 on the SPR surfaces and washing away 
unbound conjugates, the blocking strand was displaced by adding the invading strand. To confirm that the 
detection prongs of the NanoCombs were able to bind to the unblocked anti-Her3 affibody-oligo conjugates, 
we introduced a second toehold-mediated exchange system that displaced the hybridization between the 
reference prong and the anti-Her2 affibody-oligo conjugate. In this manner, the NanoCombs were able to 
stay bound to the surface only if the anti-Her3 affibody-oligo conjugates were properly unblocked and were 
able to hybridize to the detection prongs. Accordingly, we did not observe significant loss of the SPR signal 
upon injection of the invading strand for the anti-Her2 affibody-oligo conjugate on samples where we 
performed unblocking of the anti-Her3 affibody-oligo conjugates (Fig. 3a-left). In contrast, the SPR signal 
decreased on surfaces that had not been treated with anti-Her3 conjugates (Fig. 3a-right). Using 
Electrophoretic Mobility Shift assay (EMSA), we further confirmed reversible blocking of the affibody-oligo 
conjugates, when performing the reactions in solution (Fig. 3b). Together, these results show that toehold-
mediated strand displacement reversibly blocked the hybridization of affibody-oligo conjugates to the 
detection prongs of the NanoCombs with high efficiency. 
 
Validation of enzymatic reactions to generate dsDNA sequences Once correct binding is established 
between the prongs of the NanoCombs and the binder oligos, two enzymatic reactions, DNA polymerization 
and cleavage, are needed to obtain the final dsDNA sequences that hold both the position and identity 
barcodes. Using SPR, we were able to monitor the release of NanoCombs and barcoded dsDNA fragments 
 4 
from the surface, following successful T4 polymerase elongation and BamHI/EcoRI cleavage reactions (Fig. 
4a,b). We further confirmed with native PAGE that we obtained the final barcoded fragments only from 
samples where both enzymatic reactions had occurred (Fig. 4c). 
 
NGS decoding of barcoded dsDNA sequences We performed NanoDeep on model SPR surfaces, in 
which we were able to tune the composition and the surface density of bound proteins. We produced SPR 
surfaces that presented ECD-Her2 and ECD-Her3 at two different surface densities (Fig. 5a-left). We treated 
the surfaces with Her2-NanoCombs and performed NanoDeep using binder libraries consisting of anti-Her2 
and anti-Her3 conjugates. To investigate whether the NGS analysis reflected the density of the proteins 
present on the surface, we correlated the SPR binding signal of the library (Fig. 5a-center) with the NGS 
reads originating from the detection prongs (detection sequences), scaled to the reads from the reference 
prongs (reference sequences). We observed that there was a correspondence between the SPR signal and the 
number of reads from the detection prongs (Fig. 5a-right). Next, we created surfaces presenting different 
combinations of the ECD-Her2, -Her3 and -EGFR (Fig. 5b-left) and performed NanoDeep using Her2-
NanoCombs and binder libraries consisting of anti-Her2, -Her3 and -EGFR conjugates. SPR analysis showed 
that the binding of each of the library binders was specific to their respective targets (Extended Data Fig.4). 
NGS analysis of the resulting barcoded dsDNA fragments showed that the detection prongs were able to 
selectively detect the proteins present in each surface. Importantly, the distribution of reads for position 
barcodes indicated unbiased probing by the detection prongs of the NanoComb.  
 
Next, we performed NanoDeep on Her2-expressing cancer cells. We confirmed that NanoDeep only 
generated reference and detection sequences when Her2-NanoCombs were pre-loaded with anti-Her2 
affibodies (Extended Data Fig.5). To verify the correlation between NGS reads from reference sequences and 
the amount of Her2-NanoCombs that were bound to the cells, we treated SKBR3 cells with increasing 
concentrations of Her2-NanoCombs. We found that there was a linear correlation between the levels of 
reference sequences and the concentration of NanoCombs. In subsequent experiments, NGS reads from 
reference sequences were used to scale the reads from detection sequences (Fig. 6a). Further, we used a 
concentration of NanoCombs of 5 µg/mL, which is in the lower region of the curve, to allow detection of 
the reference protein in its nanoenvironment and to avoid molecular crowding effects that could impair 
binding of the binder library. 
We used NanoDeep to analyse Her2 nanoenvironments in SKBR3 and MCF7 breast cancer cells, which 
exhibit high and low expression levels of Her2, respectively. The rationale for testing cell lines with different 
expression levels is that the oncogenic capacity of Her2 is associated with the effects of overexpression on 
the frequency distributions of interactions between Her2 and other EGFR family members at the cell 
membrane19-22. NGS analysis of reference sequences demonstrated that the NanoDeep approach detected the 
differences in Her2 expression levels between the two cell lines. Analysis of the detection sequences provided 
information on the Her2 nanoenvironments. As shown in the heatmaps, the occupancies of Her2, Her3 and 
EGFR were similar in the two cell lines (Fig. 6b). However, the total levels of Her2, Her3 and EGFR were 
higher in SKBR3 cells compared to MCF7 cells, supporting the notion that overexpression of Her2 leads to a 
higher number of interactions between Her2 and other EGF receptors. These results are consistent with 
previous reports showing that heterodimers between Her2 and other EGFR family members can form in 
Her2-expressing cancer cells, irrespective of Her2 expression levels22, 25. As a control, we performed 
NanoDeep on SKBR3 cells using Her3-NanoCombs and the binder library targeting Her2, Her3 and EGFR 
(Extended Data Fig.6). The number of NGS reads originating from the reference sequence of Her3-
NanoCombs were lower than those from Her2-NanoCombs, consistent with the lower levels of expression 
of Her3 compared to Her2 in SKBR3 cells. The occupancies of Her2, Her3 and EGFR in the Her3 
nanoenvironment differed from those obtained with Her2-NanoCombs. In particular, the levels of Her2 
were higher than the levels of Her3 in the Her3 nanoenvironment and vice versa for the Her2 
nanoenvironment (Fig. 6b). As a negative control, we used SH-SY5Y cells, which show minimal levels of 
expression of Her2. Accordingly, NGS analysis did not identify any reference or detection sequences 
(Extended Data Fig.7). 
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To investigate whether NanoDeep can detect differences in cellular states due to ligand binding to membrane 
receptors, we treated SKBR3 cells with HRG-β1, one of the isoforms of Heregulin growth factor. HRG-β1 
binds to Her3, inducing heterodimerization with Her237, 38 and, to a lesser extent with EGFR32, leading to 
increased cell proliferation in breast cancer cell lines22, 37, 39, 40. NanoDeep revealed that treatment of SKBR3 
cells with HRG-β1 led to increased occupancy of Her2 and Her3, and to a lesser extent EGFR, in the 
nanoenvironment of Her2 (Fig. 6c). The observed increase of Her3 in the nanoenvironment of Her2 is in line 
with the known mechanism by which HRG-β1 triggers the interaction between Her2 and Her338. Further, the 
presence of increased levels of Her2 indicates that HRG-β1 binding to Her3 promotes membrane interaction 
networks that are more complex than pairwise interactions. A molecular basis for the specific functions of 
higher-order structures has been described for EGFR, where self-association of ligand bound dimers leads to 
cooperativity in the activation of kinase domains29, 41. However, the composition and roles of higher-order 
structures in EGFR family mediated signalling are still poorly characterised.  
 
To extend the characterisation of Her2 nanoenvironments beyond EGFR family members, we expanded the 
binder library to include binders targeting integrin α5β1 and CD63, which are membrane proteins that have 
been reported to interact with Her2. Additionally, we included an aptamer targeting the transferrin receptor, 
CD71, which is expressed in SKBR3 cells and is unrelated to Her2 signalling. Integrin α5β1 is involved in 
tumour progression42-44 and both integrin α5 and integrin β1 have been shown to interact directly with Her245, 
46. CD63 is involved in regulation of endocytosis47-49 and bispecific antibodies targeting Her2 and CD63 were 
reported to promote Her2 endocytosis50. To target integrin α5β1, we used the small peptide ATN-16143-45, 51, 
which we conjugated to a DNA oligo using amine coupling (Extended Data Fig.8). We exploited the 
SpyCatcher-SpyTag system to covalently bind an anti-CD63 nanobody fused to SpyTag (see Methods) to 
SpyCatcher conjugated to a DNA oligo (Extended Data Fig.9). Further, we modified an aptamer specific for 
CD7152, 53 by extending the aptamer sequence to include a barcoded oligo (Extended Data Fig.10).  
We performed NanoDeep on SKBR3 cells using Her2-NanoCombs and a binder library that included 
binders targeting Her2, Her3, EGFR, CD63, integrin α5β1 and CD71 (Fig. 7). We found that the occupancies 
of Her2, Her3 and EGFR were comparable to those obtained when probing only EGFR family members. 
Further, we detected the presence of both CD63 and integrin α5β1 but not CD71 in the Her2 
nanoenvironment. Conversely, when we performed NanoDeep using CD71-NanoCombs, we were able to 
target CD71 but did not detect Her2, Her3 and EGFR in the nanoenvironment of CD71. Further, we found 
low levels of occupancy of CD63 and integrin α5β1. Together, these results demonstrated that NanoDeep 
can be implemented using expanded binder libraries that include several types of binders. NanoDeep has the 
potential to be a key tool in the investigation of the roles of higher-order association in EGFR family 




We developed a method for analysing protein nanoenvironments at the cell membrane, called NanoDeep. A 
simple DNA nanoassembly with encoded spatial information is used to decipher the spatial organization of 
proteins at the cell membrane, which are labelled with oligo-conjugated binders. NanoDeep combines 
multiplexed deciphering capability with nanoscale spatial resolution, complementing the information 
obtainable with light-based super-resolution methods. Whereas NanoDeep provides ensemble averaged data 
over a cell population, super-resolution imaging enables discrete measurements of individual 
nanoenvironments and allows live imaging. NanoDeep provides high resolution information within a spatial 
range defined by the dimensions of the NanoComb, whereas long spatial ranges are analysed in super-
resolution imaging. Both methods rely on the availability of specific, high affinity binders for analysing 
genetically unmodified cells. We showed that NanoDeep accommodates different types of binders, including 
affbodies, nanobodies, peptides and aptamers, which due to their small size do not limit the resolution of the 
method. The flexibility of NanoDeep regarding the types of binders facilitates further expansion of binder 
libraries. We applied NanoDeep to the analysis of the nanoenvironment surrounding the membrane protein 
Her2 and were able to simultaneously target six proteins. NanoDeep has the potential to enable a breakthrough in 
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the simultaneous analysis of the spatial distribution of many proteins at the membrane without microscopy 
measurements, providing a tool for understanding the importance of membrane protein assemblies. 
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Fig. 1: Schematic of the NanoDeep method. a, A DNA nanoassembly (NanoComb) consisting of a double stranded backbone 
with four barcoded protruding ssDNA strands (prongs) is preloaded with an oligo-conjugated binder specific for the reference 
protein and incubated with fixed cells. b, A library of binders is added, each conjugated to a ssDNA sequence bearing a barcode 
that identifies its target protein as well as a sequence that is partially complementary to the sequences of the detection prongs. c, 
During the incubation, affibody-oligo conjugates are hybridized with a blocking strand. Unblocking is promoted by toehold-
mediated displacement guided by an invading strand. d, The free 3’ ends formed by the hybridization of the prongs with the binder 
oligos function as primers for DNA polymerase. e, DNA polymerase reaction creates dsDNA sequences that contain both the 
barcodes for the relative position of the prongs within the NanoComb and for the protein that is recognized by the binder. f, 
Restriction enzymes cleave the dsDNA sequences at specific nuclease target sequences that are included in both the prongs and the 
binder oligos, leading to the release of dsDNA sequences. g, dsDNA sequences are analysed by NGS. h, Schematic representation 
of prongs and oligos conjugated to the binders, which contain binding regions complementary to each other. For the reference 
prong and the oligo conjugated to the binder targeting the reference protein (left) this region is 20-nucleotides (nt) long. For 
detection prongs and the oligos conjugated to the library binders (right) the binding region is 15-nt long; a 5-nt long bulk region is 
added to the oligo sequences of the conjugates. Binding regions are followed by a 6-nt barcode identifying the protein or the 
position, in the binder oligos or the prongs, respectively. Further, both the prongs and the binder oligos contain nuclease target 
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Fig. 2: NanoComb characterisation. a, NanoComb composed of a 100-nt ssDNA backbone and four 57- or 52-nt ssDNA 
strands (reference and detection prongs, respectively), each of which hybridizes to the backbone by means of the first 21-nt, leaving 
the remaining 36- or 31-nt ssDNA sequences to protrude from the backbone. b, In an extended DNA conformation, the total 
length of NanoComb is 34 nm and the prongs protrude from the backbone with a period of 21 bp, which corresponds to a 
distance of 7 nm, along the helical direction of the backbone. c, Real time kinetic analysis using SPR of sequential binding of the 
prongs to the backbone, which was immobilised onto the SPR sensor surface. RU, resonance units. d, The backbone alone (bb) or 
the backbone hybridised with one (bb+p1), two (bb+p1+p2), three (bb+p1+p2+p3) or all four prongs (bb+p1+p2+p3+p4), 
monitored by native PAGE (7%). One prong sequence was loaded as a control (p). e, f, The incorporation of affibody-oligo 
conjugates in the NanoCombs was verified using direct (e) and reverse (f) SPR assays. In the direct assay (e), we measured the 
hybridization of affibody-oligo conjugates to desthiobiotinylated NanoCombs immobilised on Streptavidin (SA) SPR surfaces, 
followed by measurement of ECD-Her2 binding, to verify that the affibodies preserved their ability to recognize Her2. In the 
reverse assay (f), ECD-Her2 was covalently immobilised on the sensor surface at three different surface densities. Sensorgrams 
showed sequential binding of affibody-oligo conjugates and of NanoCombs. The SPR signal obtained from NanoComb binding to 
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Fig. 3:  Toehold exchange reversibly blocked the hybridization of affibody-oligo conjugates to the NanoCombs. a, A 1:1 
mixture of ECD-Her2 and ECD-Her3 was covalently attached to the SPR surfaces of two separate flow cells. Her2-NanoCombs 
were injected and binding to the anchored ECD-Her2 was detected by an increase in the sensorgram signal. Anti-Her3 affibody-
oligo conjugates, previously hybridised with a blocking strand, were added to flow cell 1 (on the left) but not to flow cell 2 (on the 
right). In flow cell 1, a first invading strand (invading strand 1) was injected, promoting unblocking of the anti-Her3 affibody-oligo 
conjugates and hybridization to the detection prongs of the NanoComb. Importantly, we performed this step after increasing the 
temperature to 45 °C, which is below the melting temperature of the hybridization between the invading strand and the blocking 
strand but above the melting temperature of the hybridization between the invading strand and the prongs. This prevented the 
hybridization of invading strand to the prongs of the NanoCombs. Temperature was then decreased to 25 °C and the oligo tails of 
the affibody-oligo conjugates were then free to hybridize to the detection prongs of the NanoCombs. The sequences of the anti-
Her2 conjugates preloaded on the reference prong contained an added 7-nt at 3’ end in this experiment. This allowed for a second 
toehold exchange reaction that promoted the displacement of anti-Her2 conjugates from the reference prong. This caused a larger 
decrease in the SPR signal in flow cell 2, where binding of the NanoComb to the surface is mediated only by the reference prong 
(bottom-right), than in cell flow 1, where the NanoComb remains bound to the surface through the interaction of the detection 
prongs with the anti-Her3 conjugates (bottom-left). b, EMSA using native PAGE (13%) was performed on samples that 
underwent blocking/unblocking reactions in solution. The hybridization of blocking strand to affibody-oligo conjugate was 
visualised by a shift of the conjugate band (the red line indicates the level without blocking). Displacement of the blocking strand 
by the invading strand was visualised by a shift in the conjugate band and the presence of the released dsDNA fragment consisting 
of the blocking strand hybridised to the invading strand. We observed a further shift in the conjugate band when adding the 
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Fig. 4:  DNA polymerase and nuclease reactions generated barcoded dsDNA sequences. a, Schematic representation of the 
SPR assay; equivalent amounts of ECD-Her3 were covalently attached to two SPR flow cells. Anti-Her3 affibody-oligo conjugates 
bound first to the target proteins and then hybridised with the NanoCombs. To promote the release of the barcoded dsDNA 
sequences, T4 polymerase DNA elongation and restriction enzyme cleavage were performed. The enzymatic reactions were carried 
out only on flow cell 1 and flow cell 2 was used as a negative control. Finally, streptavidin that is able to bind to the desthiobiotin 
on 3’ end of NanoComb backbone, was injected over the two flow cells to detect the residual amounts of NanoCombs remaining 
on the surface. b, SPR signals of the conjugates and NanoCombs were comparable on the two flow cells. The binding of 
streptavidin was significantly reduced in flow cell 1 compared to flow cell 2, demonstrating the efficiency of the enzymatic 
reactions. c, Barcoded dsDNA sequences visualised on native PAGE (13%) after PCR amplification were recovered from flow cell 




























































































































Fig. 5: NanoDeep on model SPR surfaces. a, 1:1 mixtures of ECD-Her2 and ECD-Her3 were covalently attached to the SPR 
surfaces of two sensor chips at two different surface densities. NanoDeep was performed by first flowing Her2-NanoCombs and 
then binder libraries consisting of anti-Her2 and anti-Her3 conjugates. Binding to the anchored proteins was monitored by 
sensorgram signals, which reflect the amount of anchored proteins. NGS analyses were performed in duplicate and presented as 
mean values in the heatmap. Barcode reads from the detection sequences were scaled to the reference sequence reads. b, 
NanoDeep was performed on SPR surfaces presenting different compositions of EGFR family receptors: Her2-Her3 (top), Her2-
EGFR (middle) and a 1:1:1 mixture of Her2-Her2, Her2-Her3 and Her2-EGFR (bottom). NGS analyses were performed in 
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Fig. 6: NanoDeep on cells. a, NGS analysis revealed a linear correlation between NGS reads and the concentration of Her2-
NanoCombs. SKBR3 cells were treated with three different concentrations of Her2-NanoCombs: 0.5 µg/mL, 5 µg/mL and 30 
µg/mL. NGS reads are presented in heatmaps (left panel) and as a plot showing a linear correlation between the number of NGS 
reads of reference sequences and NanoComb concentrations (right panel). b, SKBR3 cells and MCF7 cells were grown to similar 
densities and analysed by NanoDeep using Her2-NanoCombs and anti-Her2, -Her3 and -EGFR binder libraries. All measurements 
were performed in triplicate and presented as mean values in two types of heatmaps, showing the reads from the reference 
sequences (top) and detection sequences (bottom). c, SKBR3 cells were starved for 24 h and then stimulated for 15 min with 
HRG-β1, followed by NanoDeep assay. Untreated cells were used as controls. For each position of the NanoComb, the number of 
reads of detection sequences was plotted versus the protein identity barcodes, for HRG-β1 treated cells (orange dots) and control 



































































































































































































Fig. 7: NanoDeep with expanded library. NanoDeep was performed on SKBR3 cells using Her2-NanoCombs (top) or CD71-
Nanocombs (bottom) and anti-Her2, -Her3, -EGFR, CD63, α5β1 and CD71 binder libraries. All measurements were performed in 
triplicate and presented as mean values in two types of heatmaps, showing the reads from the reference sequences (left) and 




DNA sequences  
All synthetic DNA sequences were obtained from Integrated DNA Technologies, except for the 
AbCodeCD63_library sequence which was obtained from Biomers.net. DNA sequence details are reported in 
the Supplementary Information (Supplementary Table 1). 
 
Folding, purification and electrophoretic characterisation of DNA NanoCombs  
Backbone and protruding strands (prongs) ssDNA sequences were diluted at a concentration of 1 µM and 2 






















































































































was carried out by rapid heat denaturation (80 °C for 10 min) followed by cooling to RT for 2 h. Removal of 
excess prongs was done first with washing in 50 kDa MWCO 0.5 mL Amicon centrifugal filters (Merck 
Millipore) and then by means of Streptavidin-coated magnetic beads (DYNAL MyOne Dynabeads 
Streptavidin C1- Thermofisher Scientific) as follows: beads were washed with PBS and then with 
Immobilization Buffer (5 mM Tris-HCl pH 7.5, 1 M NaCl, 0.5 mM EDTA). NanoCombs were incubated 
with beads at RT for 1 h; beads were then collected with a magnet and the supernatant was discarded. The 
elution of NanoCombs from beads was performed with 5 mM biotin (Invitrogen) for 30 min at RT. Native 
polyacrylamide gels were stained with SybrGold to visualize the NanoComb stepwise assembly (7%) and the 
purification yield (13%). 
 
Design, expression and purification of affibody-VirD2 fusion proteins  
The coding sequences of anti-Her2 (ZHer2:341), anti-Her3 (Z086992) and anti-EGFR (ZEGFR:23773) affibodies were 
synthetised (BioCat) and cloned (XhoI/BamHI) at the C-terminal of the VirD2 protein connected via a 
flexible linker (GGGGS) in the expression plasmid pET-16-b and the sequences were validated by 
sequencing. Expression and purification of recombinant proteins were carried out as previously described4 at 
the Karolinska Institutet/SciLifeLab Protein Science Core Facility. 
 
VirD2 tag mediated conjugation of oligonucleotides to affibodies and purification of conjugates  
For the conjugation reaction, protein and oligonucleotide were mixed at a 1:0.75 ratio in TKM buffer (50 mM 
Tris-HCl pH 8, 150 mM KCl, 1 mM MgCl2, 10% glycerol) and incubated at 37 ºC for 2 h. Conjugates were 
then purified from the excess oligo and the fraction of protein not conjugated by isolation from a native 
PAGE gel. Briefly, conjugates were separated from oligos and excess protein by electrophoresis by native 
PAGE (10%). The bands corresponding to the conjugates were cut and incubated overnight at 4 °C in TBS 
buffer (50 mM Tris-HCl pH 7.5, 150 mM MgCl2). Buffer with eluted conjugates was finally filtrated with 
Nylon 0.45 µM centrifugal filter (Thermofisher Scientific). 
 
Anti-CD63 binder-oligo conjugate production 
A recombinant nanobody was previously selected during a panning performed using directly extracellular 
vesicles and its characterisation indicated that it recognizes a major Extracellular Vesicles (EV) biomarker 
largely conserved in vesicles recovered from different sources5. We confirmed by SPR experiments high 
affinity binding for EV biomarker CD63. The original sequence was subcloned, fused to the SpyTag, as 
previously described6, to be used in combination with SpyCatcher7. Expression and purification of 
recombinant SpyCatcher protein with N-terminal cysteine were carried out at the Karolinska 
Institutet/SciLifeLab Protein Science Core Facility. pDEST14-Cys-SpyCatcher0028-11 was a gift from Mark 
Howarth (Addgene plasmid #102829; http:// n2t.net/addgene:102829; RRID:Addgene_102829). SpyCatcher 
was first conjugated to an oligo sequence by means of maleimide reaction: SpyCatcher was diluted to a 
concentration of 100 µM in Hepes 10 mM pH 7.0 buffer and kept reduced by the addition of TCEP in 10-
fold molar excess for 20 minutes at RT. The oligo sequence was dissolved in TE buffer (Tris 10 mM, EDTA 
1 mM, pH 8.0) and then added to SpyCatcher with a molar ratio of DNA to protein of 10:1 (250:25 µM:µM). 
After 2 h at RT the modified SpyCatcher was purified by Pierce Strong Ion Exchange Spin Columns 
(Thermofisher Scientific). SpyCatcher-oligo complex was then incubated with SpyTag-nanobody with a molar 
ratio SpyCatcher-oligo:SpyTag-nanobody of 2:1 in PBS pH 7.6 for 2 h at RT. Anti-CD63 binder-oligo 
conjugate was finally purified by means of 30 kDa MWCO 0.5 mL Amicon centrifugal filters. 
 
Anti-integrin α5β1 binder-oligo conjugate production 
The conjugation of anti-integrin α5β1 peptide ATN-161 with the DNA oligo was performed by means of 
click chemistry reaction exploiting the commercial Protein-Oligo Conjugation Kit according to the 
manufacturers’ instructions (SoluLink). The conjugation reaction was visualised spectrophotometrically by 
determining the absorbance at A354 due to the formation of the chromophoric conjugate bond. The reaction 
solution was exchanged in PBS using 7K Zeba columns. 
 
Anti-CD71 binder-oligo conjugate production 
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Anti-CD71 RNA aptamer was generated via in vitro run-off transcription. A T7 RNA polymerase promoter 
sequence (underlined) and AbCodeCD71_NC or AbCodeCD71_library sequences (in bold) were added to 
the anti-CD71 aptamer sequence to generate the template (5’ GAA TTC TAA TAC GAC TCA CTA TAG 
GGG GGT TCT ACG ATA AAC GGT TAA TGA CCA GCT TAT GGC TGG CAG TTC CCT TTT 
GGA TCC TTA GGG GCA TCC ACT CAT TCA ATA CC 3’). In vitro run-off transcription reaction was 
performed using Durascribe T7 transcription kit (Lucigen). Briefly, the DNA template and its complementary 
sequence were first diluted in annealing buffer (30 mM Hepes, 100 mM Potassium Acetate, pH 7.5) and 
heated at 95 °C for 3 min. Annealing step was performed at RT for 30 min. 1 µg of dsDNA template was 
added to 400 U of T7 RNA polymerase (Y639F mutant), 5 mM 2′-fluoro-modified CTP, 5 mM 2′-fluoro-
modified UTP, 5 mM ATP, 5 mM GTP, 10 mM DTT in RNase-free distilled water. This reaction solution 
was incubated for 4 h at 37 °C and then treated with RNase-Free DNase I for 15 min at 37 °C. Aptamer-
oligo was finally purified with RNA Clean & Concentrator-25 (Zymo Research) according to the 
manufacturer’s instructions. 
 
Functionalization of NanoCombs with anti-Her2, anti-Her3 and anti-CD71 affibody-oligo 
conjugates on reference prong (Her2-, Her3- and CD71-NanoCombs) 
NanoCombs were folded and loaded on Streptavidin-coated magnetic beads, as previously described. Anti-
Her2/anti-Her3 affibodies or anti-CD71 aptamer, conjugated with an oligo sequence that partially hybridizes 
to the reference prong and purified as described above, were incubated with the beads at RT for 2 h. Beads 
were then collected with a magnet and the supernatant was discarded. Finally, Her2-, Her3- and CD71-
NanoCombs were eluted from the beads with 5 mM biotin for 30 min at RT. 
 
Surface Plasmon Resonance assays  
Biacore T200 instrument and related reagents (GE Healthcare) were used to perform all SPR experiments. 
NanoComb assembly characterisation. SA gold sensor chip was used to immobilize desthiobiotinylated-backbone 
DNA sequence (ligand) and to verify the hybridization of the protruding strands (analyte). HBS-EP+ was 
used as running buffer. Binding/kinetics of VirD2-affibodies and affibody-oligo conjugates. ECD-Her2/-Her3/-EGFR 
proteins (AcroBiosystem), were immobilised on CM3 or CM5 sensor chip via amine coupling reactions, 
according to the manufacturers’ instructions. Binding affinity tests of the VirD2-affibodies and affibody-oligo 
conjugates were performed by injecting different concentrations of analytes in running buffer (HBS-EP+). 
The surface was regenerated with Gly-HCl pH 2.0 solution. The dissociation equilibrium constant (KD), the 
association rate constant (kon), and the dissociation rate constant (koff) were determined using the 
BIAevaluation 3.0 software, assuming a 1:1 binding model. Characterisation of the binding between conjugates and 
NanoCombs. Desthiobiotinylated-NanoCombs were immobilised on SA gold sensor chips. Then affibody-
oligo conjugates (targeting Her2) were injected over the surface at 1 µM. The binding capability of Her2 was 
verified by flowing three increasing concentrations of ECD-Her2 (0.5-5-50 nM) in single cycle kinetic mode. 
In the reverse assay, ECD-Her2 was covalently immobilised on CM3 sensor chips, reaching three different 
surface densities on independent flow cells. Next, anti-Her2 affibody-oligo conjugates (at 50 nM) and 
NanoCombs (at 400 nM) were sequentially flowed over the surface. HBS-EP+ buffer was used as running 
buffer. Toehold exchange strategy. Assay 1: Binder oligos corresponding to the DNA sequences of the affibody-
oligo conjugates, biotinylated at the 5’ end, were immobilised on SA sensor chips. Blocking strand oligos were 
injected at the concentration of 1 µM; the displacement of blocking oligo by branch migration was promoted 
by injection of 2 µM of invading strands over the surface. After that, a partially assembled NanoComb 
(backbone + prong 2 and prong 3) at 2 µM concentration was allowed to interact with the unblocked 
immobilised oligos. TE/Mg2+ buffer (10 mM Tris pH 8.0, 12.5 mM MgCl2,1 mM EDTA) was used as 
running buffer. Assay 2: ECD-Her2 and ECD-Her3 were mixed 1:1 and incubated for 1 h. Then they were 
injected over a CM5 sensor surface (two flow cells) for covalent immobilization. Her2-NanoCombs were 
injected over the surface and then anti-Her3 affibody-oligo conjugates, previously hybridised with blocking 
strand, were injected over only one of the two active flow cells. The blocking strand was then displaced by 
injection of invading strand 1; during this step the temperature was increased to 45 °C to prevent 
hybridization of invading strand to the detection prongs. Temperature was decreased to 25 °C and the system 
was left in stand-by mode for 1 h to allow hybridization of oligos of the conjugates to the detection prongs. 
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After that, invading strand 2 was injected over the surface. HBS-EP+ buffer was used as running buffer. 
Validation of enzymatic reactions. ECD-Her3 was covalently immobilised on two flow cells of CM5 sensor chip, 
reaching the same immobilization level. Anti-Her3 affibody-oligo conjugates were injected over the surface, 
followed by injection of NanoCombs in HBS-EP+ as running buffer. After that, T4 polymerase (New 
England BioLabs) at 15 units/mL was injected over the flow cell 1 in Neb2.1 buffer 1x (New England 
BioLabs) for 15 min at 12 °C. Then, first EcoRI (New England BioLabs) and afterwards BamHI (New 
England BioLabs), at 15 units/mL, were injected over the flow cell 1 in Neb2.1 buffer 1x and Cut Smart 
buffer 1x (New England BioLabs) respectively, for 15 min at 37 °C. Finally, running buffer was changed back 
to HBS-EP+ to perform the injection of Streptavidin over both flow cells 1 and 2. Binding/kinetic of Her2-and 
Her3-NanoComb. 1:1 mixtures of ECD-Her2 and ECD-Her3 were covalently attached to the SPR surfaces, on 
CM5 sensor chips. Binding of Her2- and Her3-NanoCombs was performed by injecting increasing 
concentrations in single cycle kinetic mode. Fitting was performed using a 1:1 kinetic model to determine the 
dissociation constant, KD. NanoDeep experiment. Different sensor surfaces were created by covalently 
immobilizing ECD-Her2/-Her3/-EGFR alone or in different combinations on CM5 chip. Her2-
NanoCombs were injected over the surface. After that, libraries of affiboby-oligo conjugates, previously 
hybridised with blocking strand, were injected. Toehold-mediated strand displacement and enzymatic 
reactions were performed as previously described. The digestion products of BamHI were recovered in a stop 
reaction solution (2 mM EDTA). Binding/kinetics of anti-CD63 nanobody and anti-CD63 nanobody-oligo conjugate. 
His-tagged ECD-CD63 (Sino Biological) was immobilised on NTA gold sensor chip after activation of the 
surface with 0.5 mM Ni2+. Binding affinity tests of anti-CD63 nanobody and anti-CD63 nanobody-oligo 
conjugate were performed by injecting increasing concentrations in single cycle kinetic mode. HBS-P+ with 
50 µM EDTA buffer was flowed as running buffer over the surface. KD, kon and koff were determined using 
the BIAevaluation 3.0 software, assuming a 1:1 binding model. Binding/kinetics of anti-CD71 aptamer-oligo 
conjugate. The biotinylated DNA oligo that is complementary to the oligo sequence used to modify the 
aptamer was anchored to a SA sensor chip. Aptamer-oligo conjugate was immobilised to the surface through 
DNA-RNA hybridization. Increasing concentrations of ECD-CD71 (Sino Biological) were injected in 
running buffer (HBS-EP+) over the surface in single cycle kinetic mode to determine kinetic constants (KD, 
kon and koff). 
 
Micropatterned surfaces presenting ECD-Her2 or ECD-Her3 
Active surfaces suitable for protein immobilization were designed and fabricated by functionalization of 
silicon wafers with patterned Carboxymethyl-Dextran. In particular, surfaces were first coated with patterns 
of hydrophylic/hydrophobic surfaces by growing a Self Assembled Monolayer (SAM) of octadecyl trichloro 
silane (OTS) that provides the hydrophobic feature, and (3-Aminopropyl)triethoxysilane (APTES) that 
generates reactive regions for adhesion of Dextran. In the second step, Carboxymethyl-Dextran was 
deposited on the patterned reactive regions by spin coating. Carboxyl groups of dextran matrix are 
subsequently exploited for anchoring ECD-Her2 and ECD-Her3 through covalent amine coupling, as 
described above for SPR surfaces. 
 
Cell culture and cell samples preparation 
Human cancer cell lines SKBR3 and MCF7 (American Type Culture Collection; cell lines were authenticated 
and tested negative for mycoplasma contamination by the manufacturer) were cultured in 5% CO2 at 37 °C in 
DMEM (Gibco) supplemented with 10% fetal bovine serum (Thermofisher Scientific) and 1% penicillin–
streptomycin (Thermofisher Scientific). SH-SY5Y cell line (American Type Culture Collection) was cultured 
in 5% CO2 at 37 °C in RPMI (Gibco) supplemented with 10% fetal bovine serum and 1% penicillin–
streptomycin. To perform the NanoDeep protocol, cells were plated on 35 mm-diameter culture dishes and 
allowed to adhere for 24 h. Then cells were fixed with 4% formaldehyde for 20 min and washed with PBS. 
For ligand treatment assays, SKBR3 cells were starved for 24 h in serum-free medium and then stimulated for 
15 min with 7-15 nM HRG-β1 (Sigma Aldrich).  
 
NanoDeep on cells 
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Fixed SKBR3 and MCF7 cells (400,000 cells/sample), were incubated for 40 min at RT with blocking buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 250 µg/mL BSA, 15 µg/mL salmon sperm DNA 
(Invitrogen)) to prevent non-specific binding (Fig. S5). Three times washing with PBS + 0.05% Tween20 was 
then performed and, after that, Her2-NanoCombs, Her3-NanoCombs or CD71-NanoCombs were diluted in 
PBS + BSA 3% and incubated for 2 h at RT, followed by washing. Affibody-oligo conjugate libraries, 
previously hybridised with blocking strand, were next diluted in PBS + BSA 3% and added over the cells, 
followed by washing. Cells were then incubated at 45 °C and, after reaching the temperature, the 
displacement of blocking strand was performed by addition of invading strand (1 h), followed by washing. 
After that, cells were left at RT for 3 h to allow hybridization of binder oligos to the detection prongs. 
Enzymatic reactions by T4 polymerase, EcoRI and BamHI were performed as previously described. Finally, 
the digestion products of BamHI were recovered and supplemented with 2 mM EDTA to stop the reaction, 
and then concentrated by means of 3 kDa MWCO 0.5 mL Amicon centrifugal filters. 
 
Chemiluminescence assay 
Micropatterned surfaces presenting ECD-Her2 or ECD-Her3 were treated with Her2- or Her3-Nanocombs 
modified with desthiobiotin at the 3’ end of the backbone for 2 h at RT, followed by washing. 
Micropatterned surfaces were then incubated with Streptavidin conjugated with HorseRadish Peroxidase 
(HRP) (Thermofisher Scientific) for 20 min at RT, followed by washing. 150 µL of SuperSignal™ ELISA 
Pico Chemiluminescent Substrate (Thermofisher Scientific) was added and substrate conversion catalysed by 
HRP was performed for 1 min at RT. Luminescence at 425 nm was measured within 5 min after the end of 
reaction with Varioskan Lux Plate Reader (Thermofisher Scientific). For the chemiluminescence assay on 
cells, SKBR3, MCF7 or SH-SY5Y cells, plated in 96-well white plates (Corning) were treated with Her2-
NanoCombs and the chemiluminescence assay was performed as for micropatterned surfaces. 
 
PCR amplification 
GoTaq Hot start polymerase (Promega) was used for amplification of barcoded sequences derived from 
NanoDeep experiments. PCR was performed with the following conditions: 95 °C for 2 min, 30 cycles of 94 
°C for 30 s, 38 °C for 30 s and 72 °C for 3 s, and then 72 °C for 5 min. M13F sequence 
(GTTTTCCCAGTCACGAC) was added at 5’ of 17-nt primers to reduce non-specific PCR products. To 
visualise PCR products in solution, 10 µL of PCR reactions were incubated with 10 µL of SybrSafe 
(Thermofisher Scientific) for 20 min at RT. 
 
NGS sequencing 
Sequencing libraries were prepared using the ThruPLEX Tag-seq Kit (Takara Bio). 10 µL of samples from 
NanoDeep assays (performed on SPR surfaces or cells) were processed by the three-steps workflow 
described in the kit protocol. Reaction products were purified with Ampure-XP beads (Beckman Coulter) as 
follows: 0.9x volume of beads were added to 50 µL of samples and incubated for 10 min. Beads were 
collected with a magnet and the supernatant was transferred to different tubes and incubated with 1.8x 
volume of new beads for 10 min. After washing with 80% EtOH (30 s, two times), DNA was eluted with 20 
µL of EB buffer (Qiagen). 
Sequencing was performed using the NextSeq 550 instrument (Illumina), following the manufacturer’s 
standard protocol. The samples were single-end sequenced with a read length of 75 bp and 8 bp index reads.  
 
NGS Sequencing Data Analysis 
The resulting sequences were analysed through cataloguing molecules by UMI’s and identifying experimental 
barcodes using custom code written in Python and utilizing functions from the Numpy and Biopython 
libraries. Sequences were first processed to identify and catalog each read by its UMI according to the Tagseq 
pipeline. Sequences were then analysed for presence of barcode concatenation by searching by pairwise 
alignment (Smith-Waterman) for a common sequence and its reverse complement sequence which would be 
flanked by two 6-nt barcode sequences from the set of known protein identities and associated positions in 
the event of a concatenation. A threshold score of 80% match with the common sequence was used to select 
candidates for barcodes identification. Subsequent candidates were further filtered according to whether an 
80% match with one of the known barcodes could be found in the 6 nucleotide positions immediately 5’ 
 20 
upstream and 3’ downstream of the common sequence. Incidence was then tallied for each pair of barcodes 
identified and compiled into association matrices. Each tally was weighted by dividing its value by the UMI 
incidence for that particular read in order to eliminate amplification bias among associations.  
 
Statistical analysis 
Statistical analysis was carried out with GraphPad Prism (Version 8.2.1). Statistical significance was 
determined by performing two-tailed Student’s t-test. A p-value < 0.05 was considered statistically significant. 
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